$Vir Biotechnology(VIR.US)$They need better cost control and accounting practice to boost share price to a reasonable level (say 20). Section is bad because of Biden, but literally science is priced at 0 for VIR. Active investor should interfere. I’ll vote all Against in proxy, as I am not happy at all.
$Vir Biotechnology(VIR.US)$small scale experiments are good. no idea why they issue cost guidance (huge) without revenue guidance. Stupid. I don’t like new management goes back to clinical stage biotech. They hire too many people and relocate position to high salary area. AI expert in San Francisco, come on… If not sotrovimab and help of GSK made huge money, this company would have doomed.(if not stopped by Biden, would have been 40 dollar per share). I’ll start...
Morning Movers Gapping up $ZoomInfo(ZI.US)$The software stock popped 5.5% after Bank of America analyst Koji Ikeda upgraded it to buy from neutral. “We believe it is a classic self-help story that is set to outperform,” the analyst wrote, underscoring the company’s revenue growth reacceleration and new AI products as potential catalysts. $波音(BA.US)$stock rose 0.9% after Ryanair, Europe's largest airline by passenger number...
The multiple insider sales in Vir Biotechnology and zero buying activity in the last year may be a concern for potential investors. However, a fair level of insider ownership suggests a reasonable alignment of interests with shareholders.
Adobe's stock fall and FTC probe may hit future results. Pfizer's reduced earnings projection could reshape investor outlook. Vir Biotechnology's austerity measures aim at fiscal stability. Nordson's weak Q1 forecast may impact near-term stocks.
$Vir Biotechnology(VIR.US)$so stupid action. Already bought too heavy position. can only average down to 25.5. I have confidence this is a 20 to 30 dollar stock at least.
Vir Biotechnology股票討論區
I think CFO is actually fired.
good earnings but i don’t like
no idea why they issue cost guidance (huge) without revenue guidance. Stupid.
I don’t like new management goes back to clinical stage biotech. They hire too many people and relocate position to high salary area. AI expert in San Francisco, come on… If not sotrovimab and help of GSK made huge money, this company would have doomed.(if not stopped by Biden, would have been 40 dollar per share). I’ll start...
專欄Today's Morning Movers and Top Ratings: MSFT, ZI, AAL, HSY and More
Gapping up
$ZoomInfo(ZI.US)$ The software stock popped 5.5% after Bank of America analyst Koji Ikeda upgraded it to buy from neutral. “We believe it is a classic self-help story that is set to outperform,” the analyst wrote, underscoring the company’s revenue growth reacceleration and new AI products as potential catalysts.
$波音(BA.US)$ stock rose 0.9% after Ryanair, Europe's largest airline by passenger number...
Upcoming Ph 2 readouts in Q1 2024…
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$阿里拉姆制藥(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...
做業績會議了總不是壞事
新增數據:2022四季度及全年報,2023Q1
2022年4季度營收萎縮93.9%到0.49億,營業利潤均轉虧,2023Q1營收萎縮94.9%到0.63億,營業利潤和淨利潤繼續虧損。
目前公司淨資產19.7億,刨掉3.1億非流動資產還有16.6億,目前看一年虧損大約6億,這筆錢大約夠虧3年,目前倉位不重,暫時持倉觀望。
bottom confirms
I have confidence this is a 20 to 30 dollar stock at least.
暫無評論